Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2

Status

Terminated 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 2Sarcoma 1

Conditions

Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Sarcoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Neoplasm Metastasis 4Colorectal Neoplasms 4Neoplasms 3Melanoma 3Colonic Neoplasms 3Thymoma 2Rectal Neoplasms 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Myeloproliferative Disorders 2Multiple Myeloma 2Mesothelioma, Malignant 2Leukemia, Myelomonocytic, Chronic 2Esophageal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Thrombocythemia, Essential 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1

Interventions

Carboplatin 19Paclitaxel 18Fluorouracil 16Cisplatin 16pembrolizumab 15Radiotherapy 14Oxaliplatin 12Irinotecan 12Capecitabine 12Cyclophosphamide 10Radiation 8Leucovorin 8Docetaxel 8fludarabine 6Taxes 6Gemcitabine 6Trastuzumab 5fludarabine phosphate 4aldesleukin 4LY6K protein, human 4Fluorodeoxyglucose F18 4Erlotinib Hydrochloride 4Bevacizumab 4spartalizumab 3Surgical Procedures, Operative 3S 1 (combination) 3Pemetrexed 3Nivolumab 3Drug Therapy 3zimberelimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Esophageal Neoplasms × Celecoxib × Clear all
NCT01143545 2020-03-03

Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
10 enrolled
GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Esophageal Neoplasms, Lung Neoplasms, Sarcoma, Thymoma

NCT01258868 2019-12-03

Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
44 enrolled
GastrointestinalOther solid neoplasmThoracic

Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡